#MDAConference: Craig McDonald, MD, Director of the Neuromuscular Disease Clinic at @ucdavishealth.bsky.social, speaking about @sarepta.com's gene therapy delandistrogene moxeparvovec-rokl (#Elevidys) for #Duchenne at the @mda.org's 2026 Clinical & Scientific Conference in Orlando, FL.

💉 Japan approved a $2 MILLION drug — covered by public insurance.
Elevidys, a gene therapy for Duchenne muscular dystrophy, is now the priciest medicine ever under Japan's universal healthcare.
One shot. One life changed.
#GeneTherapy #Elevidys #DuchenneMD #RareDiseases

FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury The U.S. Food and Drug Administration today announced it is taking action to approve new labeling submitted by the company that includes the addition of a Boxed Warning, the agency’s most prominent sa...

When reports submitted to FAERS are investigated and used by FDA to take regulatory actions, the agency continues to be opaque about how this data and other sources led to safety actions. FDA recently took significant safety actions for #Elevidys... www.fda.gov/news-events/...

FDA Limits Duchenne Gene Therapy, Elevidys, After Two Teens Die of Liver Failure - Drugs.com MedNews MONDAY, Nov. 17, 2025 The U.S. Food and Drug Administration (FDA) is tightening restrictions on a gene therapy used to treat Duchenne muscular dystrophy after t

FDA restricts #Elevidys gene therapy for Duchenne muscular dystrophy to boys 4+ who can walk, after two teen deaths from liver failure. Treatment is no longer allowed for non-ambulatory patients. Strictest warning added about liver injury risks. www.drugs.com/news/fda-lim...

Rústica e Caminhada da Integração arrecadam fundos para tratamento de menino com doença rara Nova Hartz e Araricá promovem juntas a ação que deve auxiliar nos custos do tratamento de mais de R$ 12 milhões

Rústica e Caminhada da Integração arrecadam fundos para tratamento de menino com doença rara Nova Hartz e Araricá promovem juntas a ação que deve auxiliar nos custos do tratamento de mais de R$ 12 milhões

If you're searching for answers to 'why Elevidys was not approved by the European Medicines Agency (EMA)', you're not alone. In this article, we explore the key reasons behind the EMA’s decision and what it means for patients, families, and the future of gene therapy in the EU.

Why Elevidys Was Not Approved by the European Medicines Agency (EMA)?

You can access the comprehensive report on the reasons for the Elevidys refusal published by EMA from our web page link.

#dmd #duchenne #elevidys #eu

👉 Read More: DMDWarrioR.com

Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne drug In a setback for Sarepta Therapeutics, a New York panel has voted unanimously to recommend the state Medicaid program pause coverage of a treatment for Duchenne muscular dystrophy.

Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne drug.. statnews.com/pharmalot/20... #pharma #Medicaid #Sarepta #Duchenne #musculardystrophy #Elevidys #FDA

Kuehn Law Alert for Sarepta Therapeutics Investors: Important Steps to Take Kuehn Law is investigating potential breaches by Sarepta Therapeutics officers that may impact investors. Learn how to protect your rights today.

Kuehn Law Alert for Sarepta Therapeutics Investors: Important Steps to Take #USA #New_York #Kuehn_Law #Sarepta_Therapeutics #ELEVIDYS

Sarepta Therapeutics Investors Encouraged to Join Class Action Lawsuit Investors affected by Sarepta Therapeutics, Inc.'s alleged misleading statements about its ELEVIDYS therapy are urged to join a class action lawsuit before the deadline.

Sarepta Therapeutics Investors Encouraged to Join Class Action Lawsuit #USA #DJS_Law_Group #Eastchester #Sarepta_Therapeutics #ELEVIDYS

Pomerantz Law Firm Issues Investor Alert on Sarepta Therapeutics Class Action Lawsuit The Pomerantz Law Firm has announced a class action lawsuit against Sarepta Therapeutics due to concerns over potential securities fraud and their drug, ELEVIDYS.

Pomerantz Law Firm Issues Investor Alert on Sarepta Therapeutics Class Action Lawsuit #United_States #New_York #Pomerantz_Law_Firm #Sarepta_Therapeutics #ELEVIDYS

Sarepta Therapeutics Investors Urged to Join Class Action Lawsuit for Securities Fraud Sarepta Therapeutics investors are notified of a pending class action lawsuit. Claims are focusing on alleged securities fraud related to their gene therapy product ELEVIDYS.

Sarepta Therapeutics Investors Urged to Join Class Action Lawsuit for Securities Fraud #United_States #New_York #Class_Action #Sarepta_Therapeutics #ELEVIDYS

Drug manufacturer Catalent to lay off 350 employees Catalent is laying off hundreds at its facility in Anne Arundel County and more than two dozen workers in Baltimore.

Catalent layoffs hit hard in Maryland. Per a Reddit post, these layoffs are in a unit that serves Sarepta Therapeutics.

#MedSky #Elevidys #Duchenne #NeuroSky #neurology #rarediseases

Investors Urged to Join Class Action Against Sarepta Therapeutics for Alleged Securities Fraud Investors who faced losses in Sarepta Therapeutics due to alleged securities fraud are encouraged to join a class action lawsuit led by Levi & Korsinsky.

Investors Urged to Join Class Action Against Sarepta Therapeutics for Alleged Securities Fraud #USA #New_York #Levi_&_Korsinsky #Sarepta_Therapeutics #ELEVIDYS

Sarepta Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses Pomerantz LLP has initiated a class action against Sarepta Therapeutics amid serious investor concerns following the tragic outcomes linked to its product ELEVIDYS.

Sarepta Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses #USA #New_York #Pomerantz_LLP #Sarepta_Therapeutics #ELEVIDYS

Investors of Sarepta Therapeutics Have Deadlines to Take Action in Class Action Lawsuit Sarepta Therapeutics investors facing substantial losses have until August 25, 2025, to lead a class action lawsuit against the company for alleged violations. Act now!

Investors of Sarepta Therapeutics Have Deadlines to Take Action in Class Action Lawsuit #USA #San_Diego #Class_Action #Sarepta_Therapeutics #ELEVIDYS

Faruqi & Faruqi Investigates Sarepta Therapeutics for Potential Investor Claims Sarepta Therapeutics faces scrutiny as Faruqi & Faruqi law firm investigates claims of misleading information regarding their ELEVIDYS treatment safety.

Faruqi & Faruqi Investigates Sarepta Therapeutics for Potential Investor Claims #USA #New_York #Faruqi_&_Faruqi #Sarepta_Therapeutics #ELEVIDYS

Pomerantz Law Firm Highlights Class Action Against Sarepta Therapeutics for Investor Losses An urgent notice for Sarepta Therapeutics investors highlights a class action lawsuit amidst significant losses from alleged fraudulent practices. Deadline approaches.

Pomerantz Law Firm Highlights Class Action Against Sarepta Therapeutics for Investor Losses #USA #New_York #Pomerantz_Law_Firm #Sarepta_Therapeutics #ELEVIDYS

Join the Class Action Against Sarepta Therapeutics by August 2025 to Protect Your Investments Shareholders of Sarepta Therapeutics have until August 25, 2025, to join a class action lawsuit regarding safety claims for ELEVIDYS therapy. Act now.

Join the Class Action Against Sarepta Therapeutics by August 2025 to Protect Your Investments #USA #New_York #Class_Action #Sarepta_Therapeutics #ELEVIDYS

Sarepta Therapeutics Faces Severe Drop in Share Prices Following Third Patient's Death Amid Legal Action Sarepta Therapeutics has seen its stock plummet 36% after the tragic death of a third patient involved in trials, leading to significant legal ramifications.

Sarepta Therapeutics Faces Severe Drop in Share Prices Following Third Patient's Death Amid Legal Action #None #Patient_Safety #Sarepta_Therapeutics #ELEVIDYS

Gross Law Firm Alerts Sarepta Therapeutics Shareholders About Lead Plaintiff Deadline in 2025 Notice for Sarepta Therapeutics shareholders regarding the lead plaintiff deadline in an ongoing lawsuit, set for August 25, 2025.

Gross Law Firm Alerts Sarepta Therapeutics Shareholders About Lead Plaintiff Deadline in 2025 #United_States #New_York #Gross_Law_Firm #Sarepta_Therapeutics #ELEVIDYS

| InsideHealthPolicy.com

FDA's #Prasad was requiring evidence that #Elevidys $3.2 million gene therapy is safe and effective, so #Laura Loomer made sure he no longer works there. We say FDA must require better evidence on Elevidys to restore trust in #FDA and in that treatment.
insidehealthpolicy.com/share/149817

STAT breaks down the confusing, heartbreaking Sarepta saga In the latest episode of STATus Report, Alex Hogan breaks down the confusing, heartbreaking saga of Sarepta and its gene therapy for Duchenne muscular dystrophy.

📽️STAT breaks down the confusing, heartbreaking Sarepta saga: @alexhogan.bsky.social discusses #Elevidys from approval thru Tues PM's news that Vinay Prasad is out at the #FDA. @adamfeuerstein.bsky.social joins, and we hear from a mother whose son has #Duchenne www.statnews.com/2025/07/30/s...

Legal Investigation Launched: Faruqi & Faruqi Examines Sarepta Therapeutics for Investor Claims Faruqi & Faruqi, a prominent securities law firm, is investigating claims on behalf of Sarepta Therapeutics investors, spotlighting significant financial losses.

Legal Investigation Launched: Faruqi & Faruqi Examines Sarepta Therapeutics for Investor Claims #United_States #New_York #Faruqi_&_Faruqi #Sarepta_Therapeutics #ELEVIDYS

Sarepta reanudará próximamente los envíos de ELEVIDYS a los centros de cuidado para el tratamiento de pacientes ambulatorios con Duchenne.

🔗Lee el artículo completo en el siguiente link: lnkd.in/erwmDCDW

#TheAkariFoundation #DistrofiaMuscularDeDuchenne #SareptaTherapeutics #ELEVIDYS

#Sarepta has restarted distribution of its #Duchenne muscular dystrophy gene therapy #Elevidys – but only for patients who can walk.

pharmaphorum.com/news/fda-giv...

FDA: ‘Elevidys Gene Therapy Will Continue to Be Used in Ambulatory DMD Patients’ In a statement Monday, it said the FDA's swift action eliminated a problem with Sarepta, allowing Elevidys to return to the market without another safety study as had been feared.

FDA: ‘Elevidys Gene Therapy Will Continue to Be Used in Ambulatory DMD Patients’

#dmd #sarepta #roche #elevidys #fda #duchenne

👉 Read More: DMDWarrioR.com

Investors Seek Leadership Roles in Sarepta Therapeutics Fraud Case Rosen Law Firm invites Sarepta Therapeutics investors to participate in a significant securities fraud lawsuit. Investors can join the class action before the August deadline.

Investors Seek Leadership Roles in Sarepta Therapeutics Fraud Case #United_States #New_York #Rosen_Law_Firm #Sarepta_Therapeutics #ELEVIDYS

Sarepta Therapeutics Investors Reminded of Class Action Lawsuit Deadlines and Issues Investors in Sarepta Therapeutics are reminded of the impending class action lawsuit deadlines and allegations about the company's gene therapy.

Sarepta Therapeutics Investors Reminded of Class Action Lawsuit Deadlines and Issues #United_States #New_York #Gross_Law_Firm #Sarepta_Therapeutics #ELEVIDYS

Pomerantz Law Firm Proceeds with Class Action Against Sarepta Therapeutics Over Investment Losses Pomerantz LLP is guiding investors impacted by Sarepta Therapeutics' stock decline in a class action lawsuit with significant deadlines approaching.

Pomerantz Law Firm Proceeds with Class Action Against Sarepta Therapeutics Over Investment Losses #USA #New_York #Pomerantz_Law_Firm #Sarepta_Therapeutics #ELEVIDYS